Ondamac

Quick links to important sections

Ondamac

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondamac

Ondamac is a prescription-only pharmaceutical product used for the management and prevention of severe nausea and vomiting. Its core active compound, Ondansetron, places it within a highly specific therapeutic grouping dedicated to controlling the body's emetic (vomiting) response. This medicine is intended for systemic action, meaning it is absorbed into the bloodstream to reach its targets both in the gastrointestinal tract and the central nervous system.

Property Description
Active ingredient Ondansetron
Form Tablet, Oral Film, Injection Solution
Pharmacological class Antiemetic Agent
Specific class Selective 5-HT3 receptor antagonist
Origin Synthetic Compound

What Type of Medicine is Ondamac (Ondansetron)?

Ondamac belongs to the therapeutic class of antiemetic agents, and more precisely, it is classified as a Selective 5-HT3 receptor antagonist. The active ingredient, Ondansetron, is a synthetic compound that operates as a single-ingredient product. This type of antiemetic is clinically recognized for its targeted effectiveness, particularly in scenarios where nausea is chemically induced.

How is Ondamac Classified (Selective 5-HT3 Antagonist)?

The drug earns its classification because it selectively blocks the action of the chemical messenger serotonin at the specific 5-HT3 receptors. By functioning as an antagonist, Ondansetron prevents serotonin from binding to and activating these receptors. This mechanism is central to its general therapeutic purpose: to provide reliable prevention of nausea and vomiting.

What are the Available Forms of Ondamac?

To ensure effective and flexible systemic delivery, Ondamac is produced in several physical forms, including conventional oral tablets, rapidly dissolving oral films (ODTs), and a sterile solution for injection. This range of options is important as it ensures the medication can be administered successfully even when a patient is actively vomiting or unable to swallow.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ondansetron

What side effects are possible with Ondamac?

Possible Side Effects and Safety Information

The safety profile for Ondamac (Ondansetron) is formally classified by government regulatory authorities based on the frequency and system affected, distinguishing between common reactions and serious adverse events.

Commonly Documented Adverse Reactions

Adverse reactions that are classified as Very Common or Common based on regulatory standards primarily involve the nervous and gastrointestinal systems. Headache is consistently classified as a Very Common effect. Common reactions documented in official labeling include constipation, diarrhea, and dizziness.


System-Organ Class (SOC) Safety Concerns

The official safety information highlights potential effects across major system groups:

  • Cardiac Disorders: Concerns include QT interval prolongation and the potential for a serious, uncommon arrhythmia known as Torsade de Pointes.
  • Nervous System Disorders: Reactions documented include seizures and, rarely, movement disorders (extrapyramidal reactions).
  • Immune System Disorders: Rare, but serious, hypersensitivity reactions and anaphylaxis are explicitly noted.

Serious Adverse Reactions and Constraints

The label documents specific serious adverse reactions and safety constraints. The risk of Serotonin Syndrome is noted, particularly when the medicine is used alongside other serotonergic agents. Cases of Myocardial Ischemia have also been documented, often following intravenous administration. A key regulatory constraint is the absolute prohibition of use with Apomorphine due to the risk of profound hypotension. Use is also restricted in individuals with a history of congenital Long QT Syndrome or severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define specific clinical manifestations and severe risks associated with Ondamac (Ondansetron) overdose, requiring immediate medical attention for certain presentations.

Feature Documented Regulatory Statement
Documented Manifestations Overdose cases have included specific presentations such as sudden blindness (amaurosis) of short duration, severe constipation, hypotension with faintness, and transient second-degree heart block.
Severe/Life-Threatening Risks The regulatory profile highlights the risk of QT interval prolongation (a dose-dependent effect), post-marketing cases of Torsade de Pointes, and the development of Serotonin Syndrome, which has been reported following overdose alone.

Official Regulatory Actions

Patients should be managed with appropriate supportive therapy, as no specific antidote is known for Ondansetron overdose. Urgent medical help must be sought if severe cardiovascular or neurological symptoms occur, including signs consistent with Serotonin Syndrome (e.g., agitation, hyperreflexia). ECG monitoring is recommended for at-risk patients due to the documented dose-related risk of cardiac electrical changes. Specifically, pediatric cases consistent with Serotonin Syndrome have been reported following high oral exposures.

Therapeutic Uses of Ondamac

What Ondamac Treats: Main Uses and Benefits

Ondamac is commonly used to help with the management and prevention of severe nausea and persistent vomiting associated with acute or disruptive episodes. This medication is applied in clinical settings that involve acute or unstable symptom patterns, primarily those triggered by medical interventions.

It is considered relevant for easing symptoms that create noticeable physiological strain across three main domains: symptoms resulting from highly emetogenic cancer therapies (chemotherapy and radiotherapy), sickness associated with surgical procedures and anesthesia (PONV), and managing severe, persistent emesis in high-risk situations like pediatric gastroenteritis or Hyperemesis Gravidarum.

“This supportive therapy is applied when symptoms escalate, and short-term symptomatic assistance is needed.”

Ondamac helps address symptom clusters that may become intense or disruptive, providing relief that contributes to improved comfort during difficult episodes. It assists with maintaining stability by easing the overall symptom burden, particularly when symptoms interfere with routine activities during recovery or treatment.


Quick Fact: Relief for Acute Sickness
This medication is primarily used to address symptoms associated with acute or disruptive episodes that follow medical procedures or chemical treatment.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ondamac? (Official Regulatory Information)

Official regulatory documents define specific populations who are prohibited from using Ondamac and groups requiring special caution or dose adjustment.

Absolute Prohibitions (Contraindications)

Ondamac is strictly contraindicated for patients with:

  • A known hypersensitivity to the drug or any of its components.
  • Concurrent use of apomorphine (risk of severe hypotension).
  • Congenital Long QT Syndrome.
  • First trimester of pregnancy due to epidemiological findings suggesting an increased risk of orofacial malformations.

Eligibility by Age and Condition

Population Group Regulatory Status and Limitation
Pediatric Patients Use is established for children geq 6 months (for CINV) and geq 1 month (for PONV), but not below these ages.
Severe Hepatic Impairment The total daily dose must not exceed 8 mg due to reduced drug clearance.
Cardiac Risk Factors Caution and ECG monitoring are required for patients with pre-existing conditions like congestive heart failure or electrolyte imbalances (e.g., hypokalemia).
Breastfeeding Mothers Use is not recommended, as components pass into animal milk.

No dosage adjustment is typically required for patients with renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Ondamac (Ondansetron), primarily based on pharmacokinetic and pharmacodynamic mechanisms.

Formal Restrictions and Contraindications

Co-administration of Ondamac with Apomorphine is strictly contraindicated. This is a regulatory prohibition due to the risk of profound hypotension and potential loss of consciousness.

Pharmacodynamic and Metabolic Interactions

Category Interacting Substances/Class Official Regulatory Statement
Pharmacodynamic Serotonergic Agents (e.g., SSRIs, Tramadol) Concurrent use increases the risk of Serotonin Syndrome due to additive effects on serotonergic activity.
Pharmacodynamic QT-Prolonging Drugs Increases the combined risk of additive QT prolongation and subsequent serious arrhythmias.
Pharmacokinetic CYP Enzyme Inducers (e.g., Phenytoin, Rifampin) Causes increased drug clearance via hepatic CYP3A4, resulting in decreased systemic exposure of Ondamac (lower blood concentrations).

This medicine's clearance is documented as reduced in patients with severe hepatic impairment, resulting in a prolonged plasma half-life. Furthermore, the herbal product St. John's Wort may decrease systemic exposure by acting as a CYP3A4 inducer.

Mechanism of Action

Selective Blockade of the 5-HT3 Receptor

Ondamac's core mechanism involves the highly specific selective antagonism of the Serotonin Type 3 ( 5-HT3) receptor. By binding to and blocking this receptor, the drug prevents the endogenous signaling molecule, serotonin, from initiating neural signals. This molecular action targets a key control point in the reflex, resulting in reduced influence of the mediator on central control systems.


Dual Action in Central and Peripheral Emetic Pathways

The drug's mechanism is defined by its dual site of action, engaging both peripheral and central signaling pathways. Peripherally, it blocks 5-HT3 receptors on the vagal afferent nerves in the gut; centrally, it blocks the same receptors in the brain's Chemoreceptor Trigger Zone (CTZ). This coordinated interference with the afferent signal cascade interrupts the afferent signal cascade and alters the dynamics within the targeted pathways.


Mechanistic Constraints and Specificity

Ondamac's specific mechanism means its efficacy is constrained to pathways where serotonin activation of the 5-HT3 receptor is the dominant trigger. The drug does not modulate pathways mediated by other signaling systems, such as the H1 (histamine) receptors involved in motion sickness, which functionally constrains the mechanism to 5-HT3-mediated pathways.

Dosage and Administration Information

Ondamac (Ondansetron) is used according to strict protocols that define administration based on the type of medical procedure. The primary governing principle is prophylactic timing: the medicine must be administered before the emetogenic event, such as chemotherapy, radiation, or the induction of anesthesia.

Official Dosing Regimens

The dosing is highly specific and is determined by the emetogenic potential of the therapy received. For highly emetogenic chemotherapy, the regimen may involve a single 24 mg oral dose or up to three separate weight-based 0.15~mg/kg doses (maximum 16~mg per dose) given intravenously. Oral continuation therapy, where applicable, involves repeated doses (e.g., 8~mg) given at scheduled intervals (e.g., every 8 or 12 hours) for 1 to 5 days post-treatment.

Administration Routes and Conditions

Ondamac is approved for oral intake (as tablets, solution, or dissolving films) and parenteral intake (Intravenous or Intramuscular). Parenteral administration often requires specific preparation: IV doses for chemotherapy prophylaxis must be diluted in 50~mL of saline or dextrose solution and infused over at least 15 minutes. Orally disintegrating films should be handled with dry hands and allowed to dissolve on the tongue. For patients with severe hepatic impairment (Child-Pugh score ge 10), the total daily dose is restricted and must not exceed 8~mg.

Recent Clinical Evidence

Research Evidence Overview: Clinical Evaluation of Ondamac

This overview describes the official research that has been conducted to study Ondamac (Ondansetron), focusing on the types of clinical evaluations performed, the outcomes measured, and where scientific uncertainty remains. This summary is strictly based on findings documented in authoritative government and intergovernmental sources, and it is not intended as medical advice.


Evidence for Use in Chemotherapy- and Radiotherapy-Induced Sickness

The most extensive body of evidence for Ondamac is relevant in trials assessing short-term or episodic symptom patterns associated with cancer treatment. Researchers have primarily used Randomized Controlled Trials (RCTs) and Systematic Reviews to study the role of the agent in addressing nausea and vomiting linked to both chemotherapy (CINV) and radiation (RINV). These studies involved populations of both adults and children undergoing treatments with various levels of emetic risk. The studies monitored outcomes related to physical discomfort, including the complete absence of vomiting and the frequency of requiring rescue medication. Findings describe patterns observed in the studies where use of Ondamac was studied in trials that reported high rates of control for some symptoms, particularly the patterns of vomiting incidence during the acute (first 24 hours) phase following chemotherapy.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Ondamac was evaluated in a large number of RCTs and Meta-analyses focused on managing sickness that follows surgical procedures and anesthesia. This evidence is relevant in trials assessing short-term or episodic symptom patterns in the recovery room. The populations included adults and children categorized as being at high risk for PONV. Research describes that its use for prevention (before symptoms start) was observed in studies that reported specific patterns related to symptom frequency than its use for treating symptoms that were already established. Follow-up durations were limited, focusing mainly on the immediate recovery period.

Areas of Uncertainty and Remaining Research Gaps

Evidence is limited regarding the long-term effects of single-agent use beyond the first few days post-treatment across all indications. Evidence quality varies across studies, and subgroup findings are uncertain for specific populations, such as very frail or older adults (age over 65). The research provides findings describe group patterns, not personal outcomes, and data for certain groups remain insufficient, particularly concerning comorbidities.

Key Studies & References Clinical Practice Guideline: Treatment of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum

Frequently Asked Questions (FAQ)

Common questions about Ondamac (FAQ)

Q: How quickly should I expect Ondamac to start working?

Official information indicates how quickly the active ingredient enters the bloodstream. The time for the drug to reach its highest concentration in the blood, known as the peak plasma concentration, is officially reported as approximately 1.5 hours following a single oral dose. This timeframe describes the body’s general processing of the medication.

Q: Can Ondamac be taken with common cold and flu medicines?

Regulatory documents suggest caution when combining Ondamac with other medications that increase the body’s serotonin levels. Some common cold and flu medicines contain ingredients like dextromethorphan (a cough suppressant), which can potentially increase the risk of Serotonin Syndrome when used concurrently with Ondamac.

Q: Does alcohol interact with Ondamac?

Formal studies on the drug-to-drug interaction between Ondamac and alcohol are limited. However, official safety information indicates that consuming alcohol may intensify some of the drug’s documented central nervous system side effects, such as headache, fatigue, and dizziness.

Q: Can Ondamac be used by children?

The medicine’s regulatory approval includes its use in pediatric patients for preventing nausea and vomiting in specific settings. Use is established for children 6 months of age for chemotherapy-induced symptoms and for children 1 month of age for post-operative symptoms.

Q: Is Ondamac known to affect mood or mental health?

Official adverse event reports have documented conditions such as anxiety as a mild side effect. Furthermore, the risk of Serotonin Syndrome is noted, which is a rare but serious condition involving changes in mental status such as agitation or hallucinations.

Q: What happens if I miss taking a dose of Ondamac?

Patient instructions provided in regulatory documents address specific administration failures. In the event of vomiting within 30 minutes of taking the medicine, the official guidance documents describe a protocol where the same amount of medicine is to be administered again.

Q: Is Ondamac a type of painkiller?

No. Official labeling defines Ondamac as an antiemetic agent, meaning it is used for preventing and treating nausea and vomiting. It belongs to the specific class of 5-HT3 receptor antagonists and is not classified solely as an analgesic (painkiller).

Q: Why is Ondamac prescribed by doctors?

The medicine is officially indicated for the prevention of severe nausea and vomiting that is linked to specific medical procedures, such as highly emetogenic chemotherapy, radiation therapy, or surgery.

Q: Does Ondamac need to be taken every day?

The official protocols for Ondamac define its use as situational. Administration is often a single dose given prior to a procedure or a short-term, scheduled course following an event, such as for 1 to 5 days post-chemotherapy. It is not generally prescribed as a daily maintenance drug.

Q: Is Ondamac considered a short-term or long-term medication?

Studies and official information indicate that the drug’s use focuses on short-term or episodic symptom management. Typical treatment courses are related to specific medical events, such as surgery or chemotherapy, and usually last only a few days.

Q: Are there any common supplements that should be avoided with Ondamac?

Regulatory warnings indicate that the herbal product St. John’s Wort may reduce the concentration of the medicine in the bloodstream. This is because St. John's Wort can increase the body's clearance of the drug.

Q: Do I need a special diet while taking Ondamac?

Regulatory documents defining administration and use do not impose any requirement for a special or restrictive diet during the course of treatment with this medicine.

Q: Is it normal to feel tired when first starting Ondamac?

Fatigue, or a feeling of being very tired or weak, is listed in official documentation as a commonly reported adverse reaction. This type of effect is observed in multiple patient groups.

Q: Why do some people say Ondamac makes them dizzy?

Dizziness is formally classified in regulatory safety documents as a Common adverse reaction. The drug works by blocking serotonin receptors in both the gut and the central nervous system, which may affect balance or equilibrium in some individuals.

Q: Is Ondamac an opioid or controlled substance?

The medicine is classified as a prescription-only drug and is not scheduled as a controlled substance or opioid according to major regulatory bodies. It is not known to carry a risk of physical dependence.

Q: How does taking Ondamac relate to driving or operating machinery?

Because some patients may experience side effects such as dizziness or fatigue, regulatory patient information advises caution when performing skilled activities. Patients are advised to wait until they are aware of how the medicine affects them before engaging in activities like driving or operating machinery.

Q: Are there different strengths of Ondamac, and how do they differ?

Ondamac is manufactured in several strengths to allow for flexible use depending on the treatment protocol. Oral tablets and orally disintegrating films are typically available in 4 mg, 8 mg, 16 mg, and 24 mg strengths.

Q: Is Ondamac sold over the counter in some countries?

Ondamac (Ondansetron) is consistently classified globally as a prescription-only medicine. It is not approved by major regulatory bodies for over-the-counter sales.

Q: What is the shelf life of Ondamac?

The shelf life for the unopened product is typically documented as mathbf2 years when stored under the recommended conditions. Official instructions also note that diluted injection solutions are generally limited to mathbf24 hours of use.

Q: Is it common for people to experience headaches on Ondamac?

Yes. Headache is classified in regulatory safety documents as a Very Common adverse reaction, meaning it is one of the most frequently observed side effects, potentially affecting more than 1 in 10 people.

Q: What is the intended duration of action for a single dose of Ondamac?

The elimination half-life is the official measure of how long the drug remains in the body, indicating the time it takes for half of the drug to be removed. This half-life is approximately mathbf5.7 hours.

Q: Why is Ondamac sometimes mentioned in connection with specific surgical procedures?

The drug is formally indicated and studied for the prevention of Postoperative Nausea and Vomiting (PONV). This is a common form of sickness that can occur following surgery and the administration of anesthesia.

Q: Does Ondamac cause weight gain or loss?

Official safety documents, which formally classify common and serious adverse events, do not list either weight gain or weight loss as a common or serious reported adverse reaction.

Q: Is Ondamac a habit-forming drug?

The medicine is not classified as a controlled substance by regulatory bodies. Therefore, it is not known to be a habit-forming drug or to carry a risk of physical dependence.

Q: Why do official documents list certain foods to avoid with Ondamac?

The authoritative documents governing this medicine do not list any specific or restrictive foods that must be avoided during treatment. Any administration instructions relate only to the timing and method of taking the drug.

Q: Are there specific symptoms that mean Ondamac is not working?

The medicine’s purpose is to prevent or manage severe nausea and vomiting. The continued persistence or recurrence of these symptoms is described as the primary indicator that the intended effect has not been achieved.

Q: Are there any warnings about using Ondamac with other sedating drugs?

Because common side effects of Ondamac include dizziness and fatigue, caution is generally advised with other medications that also cause these effects. Formal warnings, however, primarily focus on interactions with serotonergic agents.

How should Ondamac be stored and disposed of?

How to Store and Dispose of Ondamac (Ondansetron)

Official labeling defines specific conditions for storing and disposing of Ondansetron to ensure product integrity and safety.

Storage Requirements

Detail Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). The injection solution may also be refrigerated.
Protection The product must be protected from light and retained in its original container or carton. The injection solution must not be frozen.
Child Safety The medicine must be kept out of the sight and reach of children in all forms.
Stability Diluted injection solutions are typically limited to 24 hours of use. Parenteral products must be visually inspected for discoloration or particulates before use.

Disposal Instructions

Unused or expired Ondansetron must be disposed of in accordance with local regulations. It is strictly advised not to dispose of the medicine via wastewater or household trash to comply with environmental protection requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondamac found in:

A-Z Index: